Secondary osteosarcoma arising after treatment for childhood hematologic malignancies

Department of Orthopaedic Surgery, Tohoku University School of Medicine, Miyagi, Japan.
Upsala journal of medical sciences (Impact Factor: 1.98). 12/2009; 114(4):249-55. DOI: 10.3109/03009730903177340
Source: PubMed


Secondary osteosarcoma arising after the treatment of hematologic malignancies other than Hodgkin's lymphoma is rare. We report two cases of secondary osteosarcoma arising after treatment for childhood hematologic malignancies (non-Hodgkin's lymphoma and lymphoblastic leukemia). A 10-year-old boy, at the age of 3, was diagnosed with non-Hodgkin's lymphoma. He received chemotherapy, radiation, and bone-marrow transplantation and then was in complete remission. At 6 years, he complained of increasing pain of the right thigh and was diagnosed with osteoblastic osteosarcoma. A 26-year-old man, at the age of 6, was diagnosed as having acute lymphoblastic leukemia (ALL). He received chemotherapy, radiation, and peripheral blood stem cell transplantation (PBSCT). At 11 years after PBSCT, he visited with the complaint of left lumbar swelling. He was diagnosed with chondroblastic osteosarcoma. In both cases alkaline phosphatase (ALP) had already increased prior to the onset of the symptom. We should rule out secondary osteosarcoma at the abnormal elevation of ALP during clinical follow-up of patients after treatment of childhood hematologic malignancies.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The extensive application of radiotherapy and the long survival of patients with malignant tumors have led to an increased incidence rate of radiation-induced osteosarcoma (RIOS), one of the most critical radiation-induced complications. Compared with primary osteosarcoma, RIOS has higher grade and poorer prognosis, which reduces the survival of patients with cancers. However, RIOS has not been fully understood in the clinical setting. This paper summarizes the latest progress at home and abroad, focusing on the incidence rate, risk factor, latency, and diagnostic criteria of RIOS. The molecular mechanism of RIOS is associated with the mutation of p53, the activation of the Wnt/β-catenin signaling pathway, and the superposition of multiple alleles. Furthermore, we discuss the differences in clinical characteristics, imaging findings, treatment, and prognosis between primary osteosarcoma and RIOS.
    No preview · Article · Jul 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Osteosarcoma as second malignancy of childhood cancers rarely occurs, and its clinical characteristics are unclear. Methods: Patients with osteosarcoma occurring as second malignancy of childhood cancers were retrospectively surveyed. Results: Of 323 patients with osteosarcoma registered in the database, 10 (3.1%) had a past history of childhood cancers. The mean age at the onset of the first childhood cancer was 2.7 years, and the diagnosis of the first childhood cancer was adrenocortical carcinoma, malignant teratoma, ovarian carcinoma, Ewing's sarcoma, and rhabdomyosarcoma in 1 patient each, and retinoblastoma in 5 patients. Osteosarcoma as second malignancy occurred 14.6 years after the first childhood cancer on average. Seven patients were alive and 3 died. In 1 patient, the cause of death was related to a complication of treatment for the first childhood cancer. Except for this patient, 7 (77.8%) of 9 patients survived with no disease (mean follow-up period: 10.9 years). Conclusions: Attention should be paid to complications of treatment for the first childhood cancer in the treatment for osteosarcoma occurring as second malignancy. The prognosis of osteosarcoma as second malignancy of childhood cancers may be more favorable than that of conventional osteosarcoma.
    No preview · Article · Jul 2014 · International Journal of Clinical Oncology